Olema Pharmaceuticals (OLMA): Price and Financial Metrics


Olema Pharmaceuticals (OLMA): $2.95

0.14 (+4.98%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OLMA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OLMA Stock Price Chart Interactive Chart >

Price chart for OLMA

OLMA Price/Volume Stats

Current price $2.95 52-week high $32.77
Prev. close $2.81 52-week low $2.00
Day low $2.73 Volume 272,108
Day high $3.00 Avg. volume 417,374
50-day MA $3.19 Dividend yield N/A
200-day MA $13.75 Market Cap 119.04M

Olema Pharmaceuticals (OLMA) Company Bio


Olema Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of targeted therapies for women's cancers. The company also focuses on OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD) that is being studied in a Phase 1/2 clinical trial for the treatment of metastatic or locally advanced ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema Pharmaceuticals was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.


OLMA Latest News Stream


Event/Time News Detail
Loading, please wait...

OLMA Latest Social Stream


Loading social stream, please wait...

View Full OLMA Social Stream

Latest OLMA News From Around the Web

Below are the latest news stories about Olema Pharmaceuticals Inc that investors may wish to consider to help them evaluate OLMA as an investment opportunity.

Olema Oncology to Present at Cowen 42nd Annual Health Care Conference

SAN FRANCISCO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), announced today that Sean P. Bohen, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview and update at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022, at 2:50 p.m. ET (11:50 a.m. PT). A live webcast of the presentation may be accessed under the Investors & Media section of Olema’s website (www.olema.com) and will be arch

Yahoo | February 22, 2022

We're Hopeful That Olema Pharmaceuticals (NASDAQ:OLMA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Yahoo | February 16, 2022

Olema reports inducement grants of 270K stock options

Olema Pharmaceuticals (OLMA) granted stock options to two new employees to buy a total 270K common shares under the company''s 2022 Inducement Plan.The company''s new Chief Medical

Seeking Alpha | February 3, 2022

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that the Company granted stock options to two new employees to purchase an aggregate of 270,000 shares of the Company's common stock, effective as of February 1, 2022. An option to purchase 250,000 sh

Yahoo | February 3, 2022

Olema Oncology Appoints Naseem Zojwalla, M.D., as Chief Medical Officer

• Dr. Zojwalla brings extensive and diverse experience in clinical development and regulatory strategy for novel oncology therapies • As part of planned leadership transition, former CMO Pamela Klein, M.D., will become a senior advisor and member of Olema’s Scientific Advisory Board SAN FRANCISCO, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commerci

Yahoo | January 31, 2022

Read More 'OLMA' Stories Here

OLMA Price Returns

1-mo 7.66%
3-mo -35.87%
6-mo -85.86%
1-year -89.57%
3-year N/A
5-year N/A
YTD -68.48%
2021 -80.53%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8723 seconds.